Celebrex Labeling For Polyps Should Emphasize Adjunctive Role, Cmte. Says
Executive Summary
Searle's Celebrex labeling for reduction of adenomatous colorectal polyps should emphasize monitoring and urge surgery when needed, FDA's Oncologic Drugs Advisory Committee suggested at its Dec. 14 meeting.
You may also be interested in...
Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market
Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.
Celebrex FAP Study Will Explore Delay Of Surgery In Pediatric Patients
Searle will examine the efficacy of Celebrex for delay of surgery in non-symptomatic adolescent patients with familial adenomatous polyposis, the company told FDA's Oncologic Drugs Advisory Committee Dec. 14.
Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market
Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.